Join to access to all OVN content. Join for Free
Season 1, Episode 12: The Future of Immuno-Oncology with Mark Frohlich

Season 1, Episode 12: The Future of Immuno-Oncology with Mark Frohlich


Share This Article


Michael Pietrack sits down with Mark Frohlich, a Harvard-trained medical Oncologist and CEO of Indapta Therapeutics! He discusses his experience in the Pharmaceutical industry as a pioneer in Immuno-Oncology. He emphasizes the importance of understanding the immune system and the integration of different approaches, including the role of artificial intelligence.

Regarding leadership, Frohlich highlights the importance of focusing on tasks that only the leader can do, giving honest feedback, and seeking out mentors for career development.

Key Points:

👨‍⚕️ Understanding the immune system is crucial in developing effective immunotherapies.

🔜The future of immunotherapy lies in integrating different approaches and leveraging artificial intelligence.

✋As a CEO, focus on tasks that only you can do and delegate other responsibilities.

🔰The "Kind Truth" help employees perform at their best.

📚Seek out mentors for guidance and career development. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Accelerated drug approvals in oncology: Pros and cons
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Article
Real-World Evidence in Oncology: Opportunities and Limitations
OVN Avatar Massimo Di Maio, Francesco Perrone, Pierfranco Conte

Real-World Evidence in Oncology: Opportunities and Limitations

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives
OVN Avatar Jaques van Heerden, MD, Mohamed Zaghloul, MD, Anouk Neven, MSc, Teresa de Rojas, MD, PhD, Jennifer Geel, MD, Catherine Patte, MD, Joyce Balagadde-Kambugu, MD, Peter Hesseling, MD, Francine Tchintseme, MD, Eric Bouffet, MD, and Laila Hessissen, MD

Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Explore OVN